Poseida Therapeutics (PSTX) said Thursday that it has nominated a new development candidate as part of its collaboration with Roche, resulting in a $15 million milestone payment from the Swiss healthcare company.
Poseida said the candidate is an allogeneic, dual CAR-T therapy that targets known antigens found in hematologic malignancies, including multiple myeloma.
The company said it and Roche had completed three programs under a collaboration agreement signed in August 2022.
Shares of Poseida Therapeutics were up more than 1% in recent trading.
Price: 2.57, Change: +0.03, Percent Change: +1.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.